These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38815414)

  • 1. Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database.
    Kondoh Y; Ito T; Saito K; Bao H; Sakamoto W
    Respir Investig; 2024 Jul; 62(4):702-709. PubMed ID: 38815414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
    Nasser M; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Hachulla E; Jouneau S; Le Lay K; Cottin V
    Respir Res; 2021 May; 22(1):162. PubMed ID: 34030695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
    Kilpeläinen M; Hirvonen T; Perkonoja K; Hirsjärvi S
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837481
    [No Abstract]   [Full Text] [Related]  

  • 5. Interstitial Lung Disease and Progressive Pulmonary Fibrosis: a World Trade Center Cohort 20-Year Longitudinal Study.
    Cleven KL; Zeig-Owens R; Mueller AK; Vaeth B; Hall CB; Choi J; Goldfarb DG; Schecter DE; Weiden MD; Nolan A; Salzman SH; Jaber N; Cohen HW; Prezant DJ
    Lung; 2024 Jun; 202(3):257-267. PubMed ID: 38713420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
    Nili M; Singer D; Hanna M
    BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 8. Proportion and predictors of FVC decline in patients with interstitial lung disease.
    Macmurdo MG; Ji X; Pimple P; Olson AL; Milinovich A; Martyn-Dow B; Pande A; Zajichek A; Bauman J; Bender S; Conoscenti C; Sugano D; Kattan MW; Culver DA
    Respir Med; 2024 Jun; 227():107656. PubMed ID: 38697229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
    Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
    Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study on the prevalence and prognosis of progressive pulmonary fibrosis: A retrospective observational study.
    Jang JH; Choe EJ; Jung SY; Ko J; Kim DW; Lee JH
    Medicine (Baltimore); 2024 May; 103(20):e38226. PubMed ID: 38758869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [No Abstract]   [Full Text] [Related]  

  • 12. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M; Steffens A; Anderson A; Brekke L; Grace Johnson M; Veeranki P; Olson AL
    J Manag Care Spec Pharm; 2024 Feb; 30(2):163-174. PubMed ID: 38308627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease.
    Kim K; Lee J; Jo YS
    Ther Adv Respir Dis; 2023; 17():17534666231212301. PubMed ID: 37991015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effect of progressive pulmonary fibrosis on patients with connective tissue disease-associated interstitial lung disease: a single center retrospective cohort study.
    Lee JK; Ahn Y; Noh HN; Lee SM; Yoo B; Lee CK; Kim YG; Hong S; Ahn SM; Kim HC
    Clin Exp Med; 2023 Dec; 23(8):4797-4807. PubMed ID: 37831431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and real-life experience in progressive pulmonary fibrosis.
    Valenzuela C; Cottin V
    Curr Opin Pulm Med; 2022 Sep; 28(5):407-413. PubMed ID: 35938201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease: A Multicenter Study.
    Khor YH; Farooqi M; Hambly N; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
    Chest; 2023 Feb; 163(2):345-357. PubMed ID: 36089070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
    Cottin V; Hirani NA; Hotchkin DL; Nambiar AM; Ogura T; Otaola M; Skowasch D; Park JS; Poonyagariyagorn HK; Wuyts W; Wells AU
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
    Fischer A; Distler J
    Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.